The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 Diabetes

Inclusion Criteria: Control group non-diabetic and non-dyslipidemic : * A person who has giver written consent * Fasting blood glucose \< 1,10 g/L * Triglycerides \< 1,50 g/L (\< 1,70 mmol/L). * HDL cholesterol \> 1,03 mmol/L (men) or \> 1,30 mmol/L (women). * LDL cholesterol \< 1,60 g/L. Type 1 diabetes group : * A person who has giver written consent * Treated type 1 diabetes (regardless of the route of insulin administration). * HbA1c \> 8.0% (\> 64 mmol/mol). Exclusion Criteria: All participants : * A person who is not enrolled in or eligible for a social security program * A person subject to a legal protective measure (guardianship, tutorship) * A person subject to a judicial protective measure * Pregnant women, women in labor, or breastfeeding women * Adults who are legally incompetent or unable to give informed consent * Minors * Systemic inflammatory disease * Medications that affect lipoprotein metabolism: immunosuppressive therapy, long-term corticosteroid therapy. Control group non-diabetic and non-dyslipidemic : * Diabetes or use of an antidiabetic medication. * Dyslipidemia or use of lipid-lowering medication. * Cardiovascular disease (history of stroke, myocardial infarction, coronary artery disease). * Kidney disease (glomerular filtration rate CKD-EPI \< 75 mL/min/1.73 m²) * Presence of metabolic syndrome defined by the presence of at least three of the following criteria (NCEP-ATP III criteria): * waist circumference \> 102 cm in men, \> 88 cm in…